Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBT Margin (2022 - 2025)

Bioregenx has reported EBT Margin over the past 4 years, most recently at 263.93% for Q4 2025.

  • For Q4 2025, EBT Margin rose 373195.0% year-over-year to 263.93%; the TTM value through Dec 2025 reached 83.23%, up 79734.0%, while the annual FY2025 figure was 83.23%, 90194.0% up from the prior year.
  • EBT Margin for Q4 2025 was 263.93% at Bioregenx, down from 15.87% in the prior quarter.
  • Over five years, EBT Margin peaked at 0.46% in Q3 2023 and troughed at 3995.88% in Q4 2024.
  • A 4-year average of 352.52% and a median of 64.17% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: tumbled -388969bps in 2024 and later skyrocketed 373195bps in 2025.
  • Year by year, EBT Margin stood at 62.09% in 2022, then plummeted by -71bps to 106.19% in 2023, then tumbled by -3663bps to 3995.88% in 2024, then surged by 93bps to 263.93% in 2025.
  • Business Quant data shows EBT Margin for BRGX at 263.93% in Q4 2025, 15.87% in Q3 2025, and 39.99% in Q2 2025.